Biosimilar Contract Manufacturing Market to be dominated by Recombinant Non-Glycosylated Proteins Type through 2028
Increasing chronic disease is expected
to drive the growth of global biosimilar contract manufacturing in the forecast
period, 2024-2028.
According to TechSci Research report,
“Biosimilar Contract Manufacturing Market - Global Industry Size, Share, Trends,
Opportunity, and Forecast, 2018-2028F”, the global biosimilar contract
manufacturing market is anticipated to grow at an impressive rate in the
forecast period, 2024-2028. This can be ascribed to the increasing prevalence
of diabetes, various type of cancers, neurological disorders, and availability
of biosimilar at lower costs over branded products across the globe.
Additionally, increasing focus on contract developments in countries like
China, India and increasing prevalence of auto immune diseases are expected to
create lucrative opportunities for the market growth in coming years. Besides,
increasing research and development activities in biotechnology industry is
further expected to support the market growth. Similarly, growing demand for
low cost and highly efficient therapeutics is also expected to create
significant growth during the forecasted period. Also, the growing demand for
manufacturing along with the growing production of microbial products such as
cytokines, hormones, enzymes, and MABs will drive the growth of the market
during the forecasted period.
However, high cost of biosimilar drugs
and subsequent therapies for the treatment of chronic diseases tend to slow
down the growth of global biosimilar contract manufacturing market in the
forecast period. Similarly, high risks and complications associated with
biosimilar drugs and lack of skilled professionals may hamper the biosimilar
contract manufacturing market growth during the forecast period. Also, poor
reimbursement scenario and lack of insurance coverage for cancer treatment in
emerging countries can further restrict the growth of global biosimilar
contract manufacturing market.
Browse over XX market data Figures
spread through XX
Pages and an in-depth TOC on "Biosimilar Contract Manufacturing Market"
The global biosimilar
contract manufacturing market
can be segmented by product, by technology, by application and by region.
Based on the Product, the global
biosimilar contract manufacturing market can be divided into Recombinant
Non-glycosylated Proteins v/s Recombinant Glycosylated Proteins. The
recombinant non-glycosylated protein segment dominated the market in 2021 and
is expected to continue maintaining its dominance throughout the forecast
period. This can be ascribed to the increasing demand for monoclonal antibodies
and the rising incidence of diabetes. Similarly, increasing cancer cases around
the world are also demanding for biosimilar contract manufacturing market
during the forecasted years.
Based on Application, the market can be
segmented into Oncology, Blood Disorders, Growth Hormonal Deficiency, Chronic
& Autoimmune Disorders, Rheumatoid Arthritis, Others. The oncology segment
is expected to dominate during the forecast period on account of increasing
prevalence of cancer, including liver, lung, blood cancers and high cost of
cancer drugs and treatment.
Major companies operating in global
biosimilar contract manufacturing market are:
- Catalent, Inc.
- Boehringer Ingelheim GmbH
- Alcami Corporation, Inc.
- Almac Group
- Lonza Group AG
- Biocon Limited
- Avid Bioservice, Inc
- Rentschler Biopharma SE
- Fujifilm Kyowa Kirin Biologics
Co., Ltd.
- WuXi Biologics, Inc.
On August 25, 2021, Cipla Limited, a leading global
pharmaceutical company, and Kemwell Biopharma Private Limited, a leading
biopharmaceutical Biopharmaceuticals Contract Manufacturing (CDMO) announced
the execution of a joint venture agreement to develop, manufacture and
commercialize biosimilars for global markets.
On August 28, 2020, iBio and Planet Biotechnology
entered into an exclusive worldwide license agreement for the development of a
COVID-19 therapeutics.
on April 13, 2021, Lonza, a leading global
Biopharmaceuticals Contract Manufacturing (CDMO)/ CMO, and Junshi Biosciences,
an innovative Chinese pharmaceutical company collaborated to accelerate the
development and manufacturing of biologics using Lonza's GS Xceed® Gene
Expression System.
Download Free Sample Report
Customers can also request
for 10% free customization on this report.
“The North
American region is expected to dominate in the global biosimilar contract
manufacturing market due to the increasingly developed biosimilar contract
organizations in the developing countries. Furthermore, increasing developed
healthcare infrastructure and increasing product introductions are further
contributing to the demand for biosimilar contract manufacturing. Similarly,
growing approvals of biosimilar drugs in recent years and growing demand for
less expensive therapeutic products, and the high prevalence of chronic
diseases are expected to drive market growth over the years. Additionally, the
increasing the incidence of non-communicable diseases such as diabetes and
autoimmune disorders is fueling the demand for cost-effective treatments and
will drive market growth over the years. Besides, increasing demand for less
expensive therapeutic products and increasing prevalence of chronic diseases
like cancers in the region are further expected to create lucrative
opportunities for the market growth” said Mr. Karan Chechi, Research Director
with TechSci Research, a research based global management consulting firm.
“Biosimilar
Contract Manufacturing Market - Global Industry Size, Share, Trends,
Opportunity, and Forecast, 2018-2028F, Segmented
By Product (Recombinant Non-glycosylated Proteins v/s
Recombinant Glycosylated Proteins), By Technology (Mammalian v/s
non-Mammalian), By Application (Oncology, Blood
Disorders, Growth Hormonal Deficiency, Chronic & Autoimmune Disorders,
Rheumatoid Arthritis, Others), By Region and Competition”, has evaluated the future growth potential of global biosimilar
contract manufacturing market and provides statistics & information on
market size, structure, and future market growth. The report intends to provide
cutting-edge market intelligence and help decision makers take sound investment
decisions. Besides, the report also identifies and analyzes the emerging trends
along with essential drivers, challenges, and opportunities in global biosimilar
contract manufacturing market.
Contact
Mr. Ken Mathews
708
Third Avenue,
Manhattan,
NY,
New York – 10017
Tel:
+1-646-360-1656